Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD (NCT07186699)

🧪 Interventions in This Study

• Non-Interventional Study (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. \* Adults ≥ 18 years of age
2. Histopathologic or cytologic diagnosis of NSCLC
3. Received or receiving curative intent treatment (e.g. surgery, radiation therapy, systemic therapy)
4. History of alcohol use or substance use disorder (other than tobacco use disorder) within the past 10 years, predating the cancer diagnosis
5. Ability to understand and the willingness to sign a written informed consent
6. English or Spanish speaking. Due to need to conduct semi-structured interviews which can develop into free-flowing conversations we need both participant and interviewer to be fluent

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California

📞 Contact the Study Coordinator

Phone: (323) 865-3935

Email: sandy.tran@med.usc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Non-Small Cell Carcinoma

• CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer — Los Angeles, California
• Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer — Buffalo, New York
• Gilteritinib for the Treatment of ALK NSCLC — Los Angeles, California
• Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer — Buffalo, New York
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment — Jonesboro, Arkansas

Explore by condition: All Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.